KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medpace Holdings (MEDP) Depreciation & Amortization (CF): 2015-2025

Historic Depreciation & Amortization (CF) for Medpace Holdings (MEDP) over the last 10 years, with Sep 2025 value amounting to $6.8 million.

  • Medpace Holdings' Depreciation & Amortization (CF) fell 4.82% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year increase of 1.27%. This contributed to the annual value of $27.8 million for FY2024, which is 15.25% up from last year.
  • Medpace Holdings' Depreciation & Amortization (CF) amounted to $6.8 million in Q3 2025, which was up 0.53% from $6.8 million recorded in Q2 2025.
  • Medpace Holdings' 5-year Depreciation & Amortization (CF) high stood at $7.2 million for Q3 2024, and its period low was $3.8 million during Q1 2021.
  • Over the past 3 years, Medpace Holdings' median Depreciation & Amortization (CF) value was $6.7 million (recorded in 2025), while the average stood at $6.6 million.
  • Per our database at Business Quant, Medpace Holdings' Depreciation & Amortization (CF) soared by 55.40% in 2021 and then declined by 4.82% in 2025.
  • Medpace Holdings' Depreciation & Amortization (CF) (Quarterly) stood at $4.2 million in 2021, then rose by 21.17% to $5.1 million in 2022, then increased by 26.62% to $6.4 million in 2023, then grew by 11.26% to $7.1 million in 2024, then decreased by 4.82% to $6.8 million in 2025.
  • Its Depreciation & Amortization (CF) was $6.8 million in Q3 2025, compared to $6.8 million in Q2 2025 and $6.7 million in Q1 2025.